How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

597 results for

Melasma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Pulse in Pulse Intense Pulsed Light for Melasma Treatment: A Pilot Study. (PubMed)

Pulse in Pulse Intense Pulsed Light for Melasma Treatment: A Pilot Study. A new type of intense pulsed light IPL with pulse-in-pulse (PIP) mode (multiple fractionated subpulses in one pulse width) has recently been developed.To evaluate the clinical efficacy and safety of PIP IPL in patients with melasma.Half of each patient's face was treated with IPL and six treatment sessions with a low-fluence quality-switched neodymium-doped yttrium aluminum garnet laser (IPL/T) every 2 weeks. The other (...) half was treated with PIP IPL. Outcome assessments included photography, modified Melasma Area and Severity Index (MASI) score, and patient satisfaction. The melanin and erythema indices were used for objective evaluation. Patients were followed up for 6 months after the last treatment.All patients completed the study successfully. On both treated sides, the melanin index decreased significantly after treatment. The modified MASI score also fell 54.4% on the PIP IPL side and 50.0% on the IPL/T side

2014 Dermatologic Surgery

142. A comparative study of low-fluence 1064-nm Q-switched Nd:YAG laser with or without chemical peeling using Jessner's solution in melasma patients. (PubMed)

A comparative study of low-fluence 1064-nm Q-switched Nd:YAG laser with or without chemical peeling using Jessner's solution in melasma patients. Although low-fluence 1064-nm Q-switched Nd:YAG laser (QSNYL) is widely used for the treatment of melasma, multiple treatments are necessary for clinical improvement. Superficial chemical peeling using Jessner's solution has been used for treatment of melasma conventionally.To evaluate the additional therapeutic effect and adverse effects of Jessner's (...) peel when combined with 1064-nm QSNYL for melasma patients in a double-blind, placebo-controlled design.Total of 52 patients were included. Patients who received 10 sessions of 1064-nm QSNYL plus chemical peeling with placebo (group A) in a two-week interval and those who received 10 sessions of 1064-nm QSNYL plus chemical peeling with Jessner's solution (group B) in a two-week interval were analyzed. Responses were evaluated using the Melasma Area and Severity Index (MASI) score, physician's

2014 Journal of Dermatological Treatment

143. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. (PubMed)

Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Melasma is an acquired hyperpigmentation on sun-exposed areas. Multiple approaches are used to treat it, but all include broad ultraviolet (UV)-spectrum sunscreens. Visible light (VL) can induce pigmentary changes similar to those caused by UV radiation on darker-skinned patients.To assess the efficacy of sunscreen with broad-spectrum UV protection that contains iron oxide as a VL-absorbing (...) pigment (UV-VL) compared with a regular UV-only broad-spectrum sunscreen for melasma patients exposed to intense solar conditions.Sixty-eight patients with melasma were randomized in two groups to receive either UV-VL sunscreen or UV-only sunscreen, both with sun protection factor ≥ 50, over 8 weeks. All patients received 4% hydroquinone as a depigmenting treatment. At onset and at conclusion of the study, they were assessed by the Melasma Activity and Severity Index (MASI; a subjective scale

2014 Photodermatology, photoimmunology & photomedicine

144. Low-Power Fractional CO2 Laser Versus Low-Fluence Q-Switch 1,064 nm Nd:YAG Laser for Treatment of Melasma: A Randomized, Controlled, Split-Face Study. (PubMed)

Low-Power Fractional CO2 Laser Versus Low-Fluence Q-Switch 1,064 nm Nd:YAG Laser for Treatment of Melasma: A Randomized, Controlled, Split-Face Study. Various laser treatments are currently available for melasma but their use remains challenging because of potential side effects.The aim of this randomized controlled study was to compare the efficacy and safety of low-fluence Q-switch 1,064 nm Nd:YAG and low-power fractional CO2 laser using a split-face design.A total of 40 female patients (...) with symmetric melasma were enrolled to the study and each side of their face was randomly allocated to either low-fluence Q-switch 1,064 nm Nd:YAG or low-power fractional CO2 laser. They were treated every 3 weeks for five consecutive sessions and followed for 2 months after the last treatment session. Response to treatment was assessed using the Melanin Index (MI) score, modified Melasma Area and Severity Index (mMASI) score, and a subjective self-assessment method.At the 2-month follow-up visit, both

2014 American journal of clinical dermatology

145. A randomized, split-face clinical trial of low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser versus low-fluence Q-switched alexandrite laser (755 nm) for the treatment of facial melasma. (PubMed)

A randomized, split-face clinical trial of low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser versus low-fluence Q-switched alexandrite laser (755 nm) for the treatment of facial melasma. Melasma is distressing for patients and challenging for physicians to treat. Clinical data from controlled comparative studies is lacking to support the efficacy, longevity, and safety of laser treatments for melasma.Compare the efficacy and safety of low fluence Q-switched (...) neodymium-doped yttrium aluminum garnet (1,064 nm) laser (Nd:YAG) versus low-fluence Q-switched alexandrite laser (755 nm) (QSAL) for the treatment of facial melasma.Twenty male and female subjects with moderate to severe mixed-type melasma on both sides of the face were randomized to six, weekly treatments with the low-fluence Q-switched Nd:YAG laser on one side and the low-fluence QSAL to the other side. Two independent investigators conducted Modified Melasma Area and Severity Index (MMASI

2014 Lasers in surgery and medicine

146. A double-blind vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of melasma in females. (PubMed)

A double-blind vehicle-controlled study of a preparation containing undecylenoyl phenylalanine 2% in the treatment of melasma in females. Undecylenoyl phenylalanine is a novel skin-lightening agent, probably acting as α-melanocyte-stimulating hormone (α-MSH) and beta-adrenergic receptor (β-ADR) antagonist.The objective of this double-blind randomized comparative study was to evaluate the efficacy and safety of a preparation containing undecylenoyl phenylalanine 2% in the topical treatment (...) of melasma in females.Forty female patients with melasma were randomly assigned to apply either the active preparation or the vehicle alone, twice daily for 12 weeks. Patients were evaluated monthly for efficacy and safety.In all, 37 patients completed the study. Of the 20 patients on active treatment, no one responded completely, but 17 (85%) had partial response. Of them, 11 had moderate improvement and six had marked improvement. Lightening of the lesions was evident from the first follow-up visit

2014 Journal of cosmetic dermatology

147. Therapeutic outcome of melasma treatment by dual-wavelength (511 and 578 nm) laser in patients with skin phototypes III-V. (PubMed)

Therapeutic outcome of melasma treatment by dual-wavelength (511 and 578 nm) laser in patients with skin phototypes III-V. Recent evidence suggests that vascular abnormalities are involved in the pathogenesis of melasma. Copper bromide (CuBr) laser, which emits dual wavelengths (511 and 578 nm), enabling simultaneous and selective destruction of melanin-containing cells and blood vessels, may be of benefit in the treatment of melasma.To investigate the efficacy and adverse effects (AEs) of CuBr (...) laser for melasma treatment in patients with skin phototypes III-V.We enrolled 24 Thai women with melasma to receive six CuBr laser treatments, 2 weeks apart. Objective (colour measurement) and subjective (clinical evaluation of photographs by three dermatologists blinded to the order of the photographs) assessments were obtained at baseline, after three and six treatments, and at the 3-month follow-up visit. A visual analogue scale (VAS) was used for patient assessment of change at baseline, after

2014 Clinical & Experimental Dermatology

148. Objective assessment of erythema and pigmentation of melasma lesions and surrounding areas in long-term management regimens with triple combination. (PubMed)

Objective assessment of erythema and pigmentation of melasma lesions and surrounding areas in long-term management regimens with triple combination. Melasma has a negative impact on quality of life since it typically occurs on the face.To evaluate the erythema and pigmentation of melasma lesions and the surrounding areas in patients receiving triple combination (TC: hydroquinone, tretinoin, and fluocinolone acetonide) regimens.Patients first received an 8-week daily TC treatment and were (...) then randomized to twice weekly or tapering regimen with TC. Melanin and erythema levels of lesions and surrounding areas were objectively measured using a narrowband reflectance spectrophotometer.Progressive reduction in the mean melanin levels was observed in the treatment phase. Following both maintenance regimens, there was no difference between melanin levels in the melasma lesions. Adverse effects were rare in both phases of the study and there was borderline reduction in erythema with regimen II.Both

2014 Journal of drugs in dermatology : JDD

149. Q-switched Nd: YAG laser versus trichloroacetic acid peeling in the treatment of melasma among Egyptian patients. (PubMed)

Q-switched Nd: YAG laser versus trichloroacetic acid peeling in the treatment of melasma among Egyptian patients. Melasma is a common disorder of facial hyperpigmentation that is often resistant to treatment.To evaluate the efficacy of trichloroacetic acid (TCA) peeling in comparison with double frequency Q-switched neodymium-doped:yttrium aluminum garnet (QS-Nd:YAG) laser in the treatment of melasma.Sixty-five adult Egyptian female patients with melasma were enrolled in this study. Wood light (...) was used for determination of the histological type of melasma. The patients were divided into 4 groups according to treatment modalities: peeling with different concentrations of TCA and double frequency QS-Nd:YAG laser. Trichloroacetic acid peeling was performed every 2 weeks up to 8 sessions, whereas laser treatment was performed every month up to 6 sessions. Melasma area and severity index (MASI) score was used before and after treatment for evaluation.Improvement percentage of MASI score

2014 Dermatologic Surgery

150. Gene Expression Profiling in Melasma in Korean Women. (PubMed)

Gene Expression Profiling in Melasma in Korean Women. There has been a paucity of data about the difference in gene expression between melasma lesional skin and normal adjacent one.Our aim was to identify novel genes involved in the pathogenesis of melasma.We performed a microarray analysis and confirmed the results on quantitative real-time polymerase chain reaction (qRT-PCR) in Korean women with melasma.There were 334 genes whose degree of expression showed a significant difference between (...) melasma lesional skin and normal adjacent one. Of these, five were confirmed on qRT-PCR. In melasma lesional skin, there were down-regulation of genes involved in the PPAR signaling pathway and up-regulation of genes involved in neuronal component and the functions of stratum corneum barrier.This result suggests that the pathogenesis of melasma might be associated with novel genes involved in the above signaling pathway in Korean women.

2014 Dermatology

151. Melasma Improving Spontaneously upon Switching from a Combined Oral Contraceptive to a Hormone-Releasing Intrauterine Device: A Report of Four Cases. (PubMed)

Melasma Improving Spontaneously upon Switching from a Combined Oral Contraceptive to a Hormone-Releasing Intrauterine Device: A Report of Four Cases. 25394784 2016 01 27 2018 12 02 1651-2057 95 5 2015 May Acta dermato-venereologica Acta Derm. Venereol. Melasma Improving Spontaneously upon Switching from a Combined Oral Contraceptive to a Hormone-releasing Intrauterine Device: A Report of Four Cases. 624-5 10.2340/00015555-2013 Locci-Molina Natalie N The Warren Alpert Medical School of Brown

Full Text available with Trip Pro

2014 Acta Dermato-Venereologica

152. A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos. (PubMed)

A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos. Melasma is a commonly acquired hyperpigmentation symmetrically distributed on the face, neck, and arms. The skin-lightening properties of Rumex occidentalis make it a therapeutic alternative to the reference standard treatment of hydroquinone (HQ).This study was conducted to evaluate the safety (...) and efficacy of 3% R. occidentalis cream versus 4% HQ cream in the management of epidermal and mixed melasma.This was a randomized, double-blind, placebo-controlled trial. Forty-five subjects with epidermal and mixed melasma were recruited to compare 3% R. occidentalis cream, 4% HQ cream, and placebo cream applied twice daily for eight weeks. Changes in pigmentation were measured every two weeks using the Melasma Area Severity Index (MASI) and a mexameter. Adverse events were noted on every visit. Patient

2014 International Journal of Dermatology

153. Melasma treatment using an erbium:YAG laser: a clinical, immunohistochemical, and ultrastructural study. (PubMed)

Melasma treatment using an erbium:YAG laser: a clinical, immunohistochemical, and ultrastructural study. Melasma is a common pigmentary disorder that remains resistant to available therapies.The aim of the present study was to evaluate the efficacy of erbium:YAG lasers in the treatment of refractory melasma and investigate the histopathological and ultrastructural changes between melasma skin and adjacent control skin before and after surgery.Fifteen Egyptian female patients with melasma (...) unresponsive to previous therapy of bleaching creams and chemical peels were included in this study. Full-face skin resurfacing using an erbium:YAG laser was performed. Clinical parameters included physician and patient assessment, and melasma area and severity index score were done. Adverse effects after laser resurfacing were recorded. Biopsies of lesions and adjacent healthy skin were stained using hematoxylin-eosin, immunohistochemically marked for Melan-A, and evaluated by electron microscopy.The

2014 International Journal of Dermatology

154. Combination Treatment of Low-Fluence 1,064-nm Q-Switched Nd: YAG Laser With Novel Intense Pulse Light in Korean Melasma Patients: A Prospective, Randomized, Controlled Trial. (PubMed)

Combination Treatment of Low-Fluence 1,064-nm Q-Switched Nd: YAG Laser With Novel Intense Pulse Light in Korean Melasma Patients: A Prospective, Randomized, Controlled Trial. Recently, intense pulsed light (IPL) and low-fluence Q-switched neodymium-doped yttrium aluminum (LF-QS-Nd:YAG) laser have been successfully used to treat melasma.To evaluate the effectiveness and safety of combined novel fractionated IPL (IPL-F) with LF-QS-Nd:YAG laser in patients with melasma.Twelve patients underwent 6 (...) treatment sessions of concomitant IPL-F and LF-QS-Nd:YAG laser (combination group), and 12 patients underwent 6 treatment session of IPL-F alone (IPL only group). Partial melasma area and severity index (MASI) scores were evaluated by 2 dermatologists using digital photography.In the combination group, the partial MASI score has significantly decreased by 47% at 1 month after the treatment (p < .05) and 50% at 2 months after the last treatment (p < .01). At 1 month and 2 months after the treatment

2014 Dermatologic Surgery

155. Cadherin 11, a miR-675 Target, Induces N-cadherin Expression and Epithelial-Mesenchymal Transition in Melasma. (PubMed)

Cadherin 11, a miR-675 Target, Induces N-cadherin Expression and Epithelial-Mesenchymal Transition in Melasma. Cadherin 11 (CDH11) was identified as a target of miR-675 by using a luciferase reporter assay. CDH11 expression and miR-675 expression were inversely correlated. CDH11 expression was not detected in melanocytes, but CDH11 expression in fibroblasts and keratinocytes positively influenced melanogenesis via the canonical Wnt and AKT activation pathways in cocultured melanocytes. CDH11

Full Text available with Trip Pro

2014 Journal of Investigative Dermatology

156. A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma

A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02110134 Recruitment Status : Completed First Posted : April 10, 2014 Last Update Posted : July 30, 2015 Sponsor: Cynosure, Inc. Information

2014 Clinical Trials

157. Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study

Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You (...) have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Efficacy and Safety of a 4% Hydroquinone Cream (Melanoderm 4%) for the Treatment of Melasma: a Randomized Controlled Split-face Study The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02095990

2014 Clinical Trials

158. Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma

Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02095756 Recruitment Status : Completed First Posted : March 26, 2014 Last Update Posted : July 31, 2015

2014 Clinical Trials

159. Prevention of Melasma Relapse During Summertime

Prevention of Melasma Relapse During Summertime Prevention of Melasma Relapse During Summertime - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Prevention of Melasma Relapse During Summertime The safety (...) Clinique Applique a la Dermatologie Study Details Study Description Go to Brief Summary: Main objective is to show that a photoprotective sunscreen having a protection against the visible light is more effective than a sunscreen having the same UVA AND UVB protection but with a low (weak) protection against the visible, to prevent the relapses of the melasma during the summertime. Condition or disease Intervention/treatment Phase Melasma Other: Sunscream with visible light protection Other: Sunscream

2014 Clinical Trials

160. Hydroquinone-salicylic acid conjugates as novel anti-melasma actives show superior skin targeting compared to the parent drugs. (PubMed)

Hydroquinone-salicylic acid conjugates as novel anti-melasma actives show superior skin targeting compared to the parent drugs. Hydroquinone (HQ) and salicylic acid (SA) are drugs for treating melasma through the mechanisms of tyrosinase inhibition and chemical peeling, respectively. Their high frequency of causing skin irritation has led to limited use of both drugs.We designed the new conjugates obtained by joining HQ and SA by the co-drug concept for evaluating cutaneous absorption (...) be the new candidates for treating melasma due to efficient skin absorption and acceptable skin tolerance.Copyright © 2014 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

2014 Journal of dermatological science

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>